Not logged in
Talk
Contributions
Create account
Log in
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Page
Discussion
Edit
Edit source
View history
Editing
Trials (North Estonia Medical Centre)
From Beacon
Jump to:
navigation
,
search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
<span style="display:none">forpatients</span> <span style="display:none">forproviders</span> <span style="display:none">forresearchers</span> <span style="display:none">estoniacountry</span> Go back to [[North Estonia Medical Centre]] '''NCTID''': NCT02205047 '''Title''': [[hasTrialTitle::Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma]] '''Study Summary''': The purpose of this study is to find out whether either trastuzumab or the combination of trastuzumab and pertuzumab with standard chemotherapy shows more activity against gastro-oesophageal adenocarcinoma than standard chemotherapy given before and after surgery and it can be safely administered. '''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC '''Intervention''': Cisplatin '''Start Date''': 2015-07-15 '''Last Updated''': 2023-02-16 '''Number of Patients''': 171 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Malignant Neoplasm of Stomach '''NCTID''': NCT04241185 '''Title''': [[hasTrialTitle::Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)]] '''Study Summary''': This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab '''Start Date''': 2020-05-19 '''Last Updated''': 2023-11-18 '''Number of Patients''': 636 '''Recruitment Status''': RECRUITING '''Condition''': Urinary Bladder Neoplasms '''NCTID''': NCT05152147 '''Title''': [[hasTrialTitle::A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers]] '''Study Summary''': This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic). '''Sponsor''': Jazz Pharmaceuticals '''Intervention''': Zanidatamab '''Start Date''': 2021-12-02 '''Last Updated''': 2023-11-18 '''Number of Patients''': 714 '''Recruitment Status''': RECRUITING '''Condition''': Gastric Neoplasms '''NCTID''': NCT05223647 '''Title''': [[hasTrialTitle::Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer]] '''Study Summary''': Studies have shown that combining chemotherapy and immune checkpoint inhibitors (ICI) prolongs survival compared with chemotherapy alone in extensive stage small-cell lung cancer (ES SCLC), but the survival benefit is modest. The main aim of this trial is to investigate whether there is a synergistic/additive effect of concurrent thoracic radiotherapy in ES SCLC patients receiving carboplatin/etoposide/durvalumab. '''Sponsor''': Norwegian University of Science and Technology '''Intervention''': Thoracic radiotherapy '''Start Date''': 2022-01-11 '''Last Updated''': 2023-04-24 '''Number of Patients''': 302 '''Recruitment Status''': RECRUITING '''Condition''': Small-cell Lung Cancer '''NCTID''': NCT05243550 '''Title''': [[hasTrialTitle::A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer]] '''Study Summary''': This Phase 3, multinational, single-arm, multicenter study will evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC). '''Sponsor''': UroGen Pharma Ltd. '''Intervention''': UGN-102 '''Start Date''': 2022-03-01 '''Last Updated''': 2023-09-29 '''Number of Patients''': 220 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Bladder Cancer '''NCTID''': NCT02163759 '''Title''': [[hasTrialTitle::A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors]] '''Study Summary''': This Phase III, double-blind, placebo and active-comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active ulcerative colitis (UC) who are naÏve to tumor necrosis factor (TNF) inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment. In addition to this study, a second Phase III trial with identical study design (GA28949; NCT02171429) was independently conducted. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Adalimumab '''Start Date''': 2014-11-04 '''Last Updated''': 2021-07-23 '''Number of Patients''': 358 '''Recruitment Status''': COMPLETED '''Condition''': Ulcerative Colitis '''NCTID''': NCT04607850 '''Title''': [[hasTrialTitle::Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions]] '''Study Summary''': A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions. '''Sponsor''': Vaccitech (UK) Limited '''Intervention''': ChAdOx1-HPV '''Start Date''': 2021-03-16 '''Last Updated''': 2023-03-29 '''Number of Patients''': 99 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': HPV Infection '''NCTID''': NCT05609968 '''Title''': [[hasTrialTitle::Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)]] '''Study Summary''': The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%). '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Sacituzumab Govitecan '''Start Date''': 2023-02-06 '''Last Updated''': 2023-11-18 '''Number of Patients''': 614 '''Recruitment Status''': RECRUITING '''Condition''': Carcinoma, Non-Small-Cell Lung '''NCTID''': NCT05947903 '''Title''': [[hasTrialTitle::Validation of the European Oncology Quality of Life Toolkit]] '''Study Summary''': The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship, and advanced terminal stages. Clinical studies and real-world data show that the use of Patient Reported Outcome Measures (PROMs) for QoL assessment in routine oncology practice has positive effects on patient wellbeing and healthcare resource utilization. However, full implementation of PROMs is not yet part of standard of care and is not adequately considered in cancer policies and programs. A comprehensive tool incorporating the perspective of patients at different stages of the disease trajectory and widely applicable across Europe is still lacking. The European Oncology Quality of Life Toolkit (EUonQoL-Kit) is a unified patient-centred tool for the assessment of QoL, developed from preferences and priorities of people with past or current cancer experience. The EUonQoL-Kit includes three electronic questionnaires, specifically designed for different disease phases (patients in active treatment, survivors, and patients in palliative care), available in both static and dynamic (Computer Adaptive Testing, CAT) versions and in several European languages. This is a multicentre observational study, with the following aims: * The primary aim is to perform the psychometric validation of the EUonQoL-Kit. * Secondary aims are to assess its acceptability, to validate the CAT version, and to provide estimates of QoL across different European countries. The EUonQoL-Kit will be administered to a sample of cancer patients and survivors from 46 European cancer centres. The sample will include patients in active treatment (group A), survivors (group B), and patients in Palliative Care (group C). Each centre will recruit 100 patients (40 from group A, 30 from group B, 30 from group C), for an overall sample size of 4,600 patients (at least 4,000 patients are assumed to be enrolled, due to an expected lower recruitment rate of 10-15%). Three sub-samples of patients (each corresponding to 10% of the total sample for each centre) will fill in an additional questionnaire: * EORTC QLQ-C30, to test concurrent validity. * Live-CAT version, to test the feasibility of such implementation. * EUonQoL-Kit, 2-7 days after the first completion, to assess test-retest reliability. '''Sponsor''': Fondazione IRCCS Istituto Nazionale dei Tumori, Milano '''Intervention''': Administration of the EUonQoL-Kit - Active Treatment questionnaire '''Start Date''': 2024-04-01 '''Last Updated''': 2023-07-19 '''Number of Patients''': 4000 '''Recruitment Status''': NOT_YET_RECRUITING '''Condition''': Cancer '''NCTID''': NCT02077868 '''Title''': [[hasTrialTitle::Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment]] '''Study Summary''': The purpose of this this trial is to prove the efficacy and safety of MGN1703 as a maintenance therapy after first-line chemotherapeutic treatment of metastatic colorectal cancer. '''Sponsor''': Mologen AG '''Intervention''': Usual Maintenance '''Start Date''': 2014-09 '''Last Updated''': 2019-09-10 '''Number of Patients''': 540 '''Recruitment Status''': UNKNOWN '''Condition''': Metastatic Colorectal Cancer '''NCTID''': NCT01322490 '''Title''': [[hasTrialTitle::A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer]] '''Study Summary''': The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer. '''Sponsor''': Bavarian Nordic '''Intervention''': PROSTVAC-V '''Start Date''': 2011-11-28 '''Last Updated''': 2019-09-04 '''Number of Patients''': 1297 '''Recruitment Status''': COMPLETED '''Condition''': Prostate Cancer Metastatic '''NCTID''': NCT01667419 '''Title''': [[hasTrialTitle::A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma]] '''Study Summary''': This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF mutation-positive melanoma at high risk for recurrence. Participants will be enrolled in two separate cohorts: Cohort 1 will include participants with completely resected Stage IIC, IIIA (participants with one or more nodal metastasis greater than \[\>\] 1 millimeter \[mm\] in diameter), or IIIB cutaneous melanoma, as defined by the American Joint Committee on Cancer (AJCC) Classification, Version 7; Cohort 2 will include participants with Stage IIIC cutaneous melanoma, as defined by this classification scheme. Within each cohort, participants will be randomized (1:1 ratio) to receive vemurafenib or matching placebo over a 52-week period. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Vemurafenib '''Start Date''': 2012-09-24 '''Last Updated''': 2019-07-23 '''Number of Patients''': 498 '''Recruitment Status''': COMPLETED '''Condition''': Melanoma '''NCTID''': NCT01905943 '''Title''': [[hasTrialTitle::A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia]] '''Study Summary''': This multicenter, open-label, single-arm study will evaluate the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in participants with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Post-Authorization Safety Study. Participants will receive 6 cycles of single-agent obinutuzumab or obinutuzumab in combination with chemotherapy at the investigator's discretion. Each participant will be followed until 30 months after the last participant has been enrolled. Total length of the study is anticipated to be approximately 5 years. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Bendamustine '''Start Date''': 2013-11-04 '''Last Updated''': 2019-10-28 '''Number of Patients''': 979 '''Recruitment Status''': COMPLETED '''Condition''': Chronic Lymphocytic Leukemia '''NCTID''': NCT02562443 '''Title''': [[hasTrialTitle::Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA]] '''Study Summary''': The study's primary objective \[in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)\], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk. '''Sponsor''': Onconova Therapeutics, Inc. '''Intervention''': rigosertib '''Start Date''': 2015-12-02 '''Last Updated''': 2022-09-26 '''Number of Patients''': 372 '''Recruitment Status''': TERMINATED '''Condition''': Myelodysplastic Syndrome '''NCTID''': NCT03869892 '''Title''': [[hasTrialTitle::Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy]]. '''Study Summary''': The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab. '''Sponsor''': Institut de Recherches Internationales Servier '''Intervention''': Trifluridine/tipiracil hydrochloride (S95005) '''Start Date''': 2019-03-21 '''Last Updated''': 2023-11-18 '''Number of Patients''': 856 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Metastatic Colorectal Cancer '''NCTID''': NCT02242942 '''Title''': [[hasTrialTitle::Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia]] '''Study Summary''': This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The time on study treatment was approximately one year and the follow-up period will be up to 9 years. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Chlorambucil '''Start Date''': 2014-12-31 '''Last Updated''': 2023-09-21 '''Number of Patients''': 445 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Lymphocytic Leukemia, Chronic '''NCTID''': NCT02425891 '''Title''': [[hasTrialTitle::A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)]] '''Study Summary''': This multicenter, randomized, double-blind study evaluated the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC). The safety of single-agent nab-paclitaxel has been determined in previous studies of participants with mBC and the safety data to date suggest that atezolizumab can be safely combined with standard chemotherapy agents. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody '''Start Date''': 2015-06-23 '''Last Updated''': 2022-07-19 '''Number of Patients''': 902 '''Recruitment Status''': COMPLETED '''Condition''': Triple Negative Breast Cancer '''NCTID''': NCT02715804 '''Title''': [[hasTrialTitle::A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma]] '''Study Summary''': The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA). '''Sponsor''': Halozyme Therapeutics '''Intervention''': Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20) '''Start Date''': 2016-03-14 '''Last Updated''': 2020-07-14 '''Number of Patients''': 492 '''Recruitment Status''': TERMINATED '''Condition''': Pancreatic Ductal Carcinoma '''NCTID''': NCT02718417 '''Title''': [[hasTrialTitle::Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)]] '''Study Summary''': This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy. The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed ovarian cancer patients. '''Sponsor''': Pfizer '''Intervention''': carboplatin '''Start Date''': 2016-05-19 '''Last Updated''': 2020-07-14 '''Number of Patients''': 998 '''Recruitment Status''': TERMINATED '''Condition''': Ovarian Cancer '''NCTID''': NCT02239120 '''Title''': [[hasTrialTitle::Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)]] '''Study Summary''': This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment). '''Sponsor''': Boehringer Ingelheim '''Intervention''': optional ASA as comedication '''Start Date''': 2014-11-27 '''Last Updated''': 2019-09-06 '''Number of Patients''': 5390 '''Recruitment Status''': COMPLETED '''Condition''': Stroke '''NCTID''': NCT04392505 '''Title''': [[hasTrialTitle::Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study]] '''Study Summary''': The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation. The hypothesis is that clinical differences in course of disease reflect underlying biological characteristics. '''Sponsor''': Oslo University Hospital '''Intervention''': Durvalumab Injection '''Start Date''': 2020-05-11 '''Last Updated''': 2022-10-25 '''Number of Patients''': 100 '''Recruitment Status''': RECRUITING '''Condition''': Cancer '''NCTID''': NCT02928406 '''Title''': [[hasTrialTitle::A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract]] '''Study Summary''': This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab '''Start Date''': 2016-11-30 '''Last Updated''': 2022-12-22 '''Number of Patients''': 1005 '''Recruitment Status''': COMPLETED '''Condition''': Urinary Tract Cancer '''NCTID''': NCT01702571 '''Title''': [[hasTrialTitle::A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment]] '''Study Summary''': This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior anti-HER2 and chemotherapy-based treatment. Participants in Cohort 1 will be drawn from the general participant population; Cohort 2 will include only Asian participants. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Trastuzumab Emtansine '''Start Date''': 2012-11-27 '''Last Updated''': 2022-04-04 '''Number of Patients''': 2185 '''Recruitment Status''': COMPLETED '''Condition''': Breast Cancer '''NCTID''': NCT04322539 '''Title''': [[hasTrialTitle::A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer]] '''Study Summary''': This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC. '''Sponsor''': Hutchison Medipharma Limited '''Intervention''': Fruquintinib '''Start Date''': 2020-08-12 '''Last Updated''': 2023-09-14 '''Number of Patients''': 691 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Metastatic Colorectal Cancer '''NCTID''': NCT04464226 '''Title''': [[hasTrialTitle::Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer]] '''Study Summary''': The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study. '''Sponsor''': Bayer '''Intervention''': Darolutamide (Nubeqa, BAY1841788) '''Start Date''': 2020-10-20 '''Last Updated''': 2023-11-18 '''Number of Patients''': 678 '''Recruitment Status''': RECRUITING '''Condition''': Cancer '''NCTID''': NCT05073315 '''Title''': [[hasTrialTitle::A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis]] '''Study Summary''': Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to severe plaque psoriasis. This multi-center study is composed of two periods: A lead-in period of treatment with Humira® followed by a randomized two parallel arm period. '''Sponsor''': Amgen '''Intervention''': Adalimumab '''Start Date''': 2021-10-04 '''Last Updated''': 2023-01-05 '''Number of Patients''': 425 '''Recruitment Status''': COMPLETED '''Condition''': Plaque Psoriasis '''NCTID''': NCT05458297 '''Title''': [[hasTrialTitle::A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)]] '''Study Summary''': The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. * Cohort A: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 2 prior systemic therapies including a Bruton's tyrosine kinase inhibition/inhibitor (BTKi), and post therapy chimeric antigen receptor T (CAR-T) cell therapy or ineligible for CAR-T cell therapy * Cohort B: Participants with relapsed or refractory RT disease after at least 1 prior systemic therapy * Cohort C: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 1 prior systemic therapy and no prior exposure to a non-covalent BTKi * Cohort D: Participants with relapsed or refractory FL and CLL relapsed or refractory disease after at least 2 prior systemic therapies and have no other available therapy * Cohort E: Participants with relapsed or refractory FL after at least 2 prior systemic therapies and have no other available therapy * Cohort F: Participants with relapsed or refractory CLL after at least 2 prior systemic therapies and have no other available therapy The primary study hypothesis is that zilovertamab vedotin monotherapy has an increased Objective Response Rate (ORR) per Lugano Response Criteria as assessed by blinded independent central review (BICR). '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Zilovertamab vedotin '''Start Date''': 2022-07-21 '''Last Updated''': 2023-11-18 '''Number of Patients''': 275 '''Recruitment Status''': RECRUITING '''Condition''': Chronic Lymphocytic Leukemia '''NCTID''': NCT01239745 '''Title''': [[hasTrialTitle::Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer]] '''Study Summary''': This non-interventional study will be conducted in several Eastern European countries to assess the safety, tolerability and efficacy of Aromasin® when it is administered in real-word setting in postmenopausal women with invasive estrogen receptor positive early breast cancer , who are disease-free after completion of 2 to 3 years of tamoxifen and continue the treatment with Aromasin® until completion of 5 years of adjuvant hormonal therapy, to understand how Aromasin® is used in routine clinical practice, to assess adherence to prescribed Aromasin® treatment and to understand reasons for its early discontinuation. '''Sponsor''': Pfizer '''Intervention''': Aromasin '''Start Date''': 2011-04 '''Last Updated''': 2012-10-31 '''Number of Patients''': 46 '''Recruitment Status''': TERMINATED '''Condition''': Breast Neoplasms '''NCTID''': NCT01572038 '''Title''': [[hasTrialTitle::A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer]] '''Study Summary''': This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line treatment in participants with metastatic or locally recurrent HER2-positive breast cancer. Participants will receive pertuzumab intravenously (IV) and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Docetaxel '''Start Date''': 2012-06-01 '''Last Updated''': 2020-09-25 '''Number of Patients''': 1436 '''Recruitment Status''': COMPLETED '''Condition''': Breast Neoplasms '''NCTID''': NCT01026142 '''Title''': [[hasTrialTitle::A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)]] '''Study Summary''': This randomized, two-arm study evaluated the efficacy and safety of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The study population consisted of female patients, whose disease had progressed during or following previous trastuzumab therapy for metastatic disease. All patients in Arm A and Arm B received trastuzumab (8 mg/kg iv as loading dose and then 6 mg/kg iv every 3 weeks thereafter) and capecitabine oral twice daily for 14 days every 3 weeks (1250 mg/m2 twice daily in Arm A and 1000 mg/m2 twice daily in Arm B). In addition, patients in Arm B received pertuzumab (840 mg iv as loading dose and then 420 mg iv thereafter) every 3 weeks. Study treatment continued until disease progression or unacceptable toxicity. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Capecitabine '''Start Date''': 2010-01-26 '''Last Updated''': 2018-08-14 '''Number of Patients''': 452 '''Recruitment Status''': COMPLETED '''Condition''': Breast Cancer '''NCTID''': NCT03498521 '''Title''': [[hasTrialTitle::A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site]] '''Study Summary''': This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Alectinib '''Start Date''': 2018-07-10 '''Last Updated''': 2023-11-18 '''Number of Patients''': 790 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Cancer of Unknown Primary Site '''NCTID''': NCT00715637 '''Title''': [[hasTrialTitle::Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study]] '''Study Summary''': Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML. The purpose of this study is to assess the relative efficacy and safety of amonafide in combination with cytarabine compared to daunorubicin with cytarabine in subjects with documented secondary AML. '''Sponsor''': Antisoma Research '''Intervention''': Daunorubicin and Cytarabine '''Start Date''': 2007-06 '''Last Updated''': 2010-10-13 '''Number of Patients''': 420 '''Recruitment Status''': UNKNOWN '''Condition''': Secondary Acute Myeloid Leukemia (Secondary AML, sAML) '''NCTID''': NCT03782207 '''Title''': [[hasTrialTitle::A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice]] '''Study Summary''': This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes and safety of atezolizumab for indications in the existing label in the real world setting of routine clinical practice. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab '''Start Date''': 2019-02-07 '''Last Updated''': 2023-11-03 '''Number of Patients''': 3040 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Urothelial Carcinoma '''NCTID''': NCT00950300 '''Title''': [[hasTrialTitle::A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer]] '''Study Summary''': In this open-label multicenter trial, participants with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil, epirubicin, and cyclophosphamide) concurrent with either SC Herceptin or IV Herceptin. After surgery, participants will receive a further 10 cycles of SC or IV Herceptin as per randomization to complete 1 year of treatment. All cycles will be 21 days in length. After the end of study treatment, participants will be followed for safety and efficacy for up to 5 years or until disease recurrence, whichever is earlier. '''Sponsor''': Hoffmann-La Roche '''Intervention''': 5-Fluorouracil '''Start Date''': 2009-10-16 '''Last Updated''': 2018-01-23 '''Number of Patients''': 596 '''Recruitment Status''': COMPLETED '''Condition''': Breast Cancer '''NCTID''': NCT04191616 '''Title''': [[hasTrialTitle::Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet]] '''Study Summary''': A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone '''Sponsor''': Amgen '''Intervention''': Carfilzomib '''Start Date''': 2020-08-06 '''Last Updated''': 2023-11-08 '''Number of Patients''': 54 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Relapsed or Refractory Multiple Myeloma '''NCTID''': NCT03003520 '''Title''': [[hasTrialTitle::A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma]] '''Study Summary''': This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, and predictive biomarkers of durvalumab in combination with R-CHOP or R2-CHOP, followed by durvalumab consolidation therapy in previously untreated subjects with high-risk diffuse large B-cell lymphoma (DLBCL). Induction treatment with R-CHOP (± lenalidomide) will last for a total of up to 6 to 8 treatment cycles (21 day cycles), and the total time on study treatment, including durvalumab consolidation, will last up to 12 months. On 05-Sep-2017, the US FDA has issued a Partial Clinical Hold on this study resulting in the discontinuation of enrollment into Arm B (Durvalumab + Lenalidomide + R-CHOP). After the US FDA Partial Clinical Hold, new eligible participants have been enrolled in Arm A (Durvalumab + R-CHOP). '''Sponsor''': Celgene '''Intervention''': Durvalumab '''Start Date''': 2017-02-28 '''Last Updated''': 2023-05-22 '''Number of Patients''': 46 '''Recruitment Status''': COMPLETED '''Condition''': Lymphoma, Large B-Cell, Diffuse '''NCTID''': NCT01307397 '''Title''': [[hasTrialTitle::A Study of Vemurafenib in Participants With Metastatic Melanoma]] '''Study Summary''': This multi-center study evaluates the safety and efficacy of vemurafenib in participants with BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV (American Joint Committee on Cancer \[AJCC\]) metastatic melanoma. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Vemurafenib '''Start Date''': 2011-03-01 '''Last Updated''': 2017-12-18 '''Number of Patients''': 3219 '''Recruitment Status''': COMPLETED '''Condition''': Malignant Melanoma '''NCTID''': NCT04895722 '''Title''': [[hasTrialTitle::Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)]] '''Study Summary''': The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab '''Start Date''': 2021-06-25 '''Last Updated''': 2023-11-18 '''Number of Patients''': 320 '''Recruitment Status''': RECRUITING '''Condition''': Colorectal Cancer '''NCTID''': NCT04717700 '''Title''': [[hasTrialTitle::Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients]] '''Study Summary''': An unrandomized phase 2 study of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up within the Nordic Multiple Myeloma Study Group '''Sponsor''': Ida Bruun Kristensen '''Intervention''': Selinexor 20 MG Oral Tablet '''Start Date''': 2021-08-18 '''Last Updated''': 2023-06-05 '''Number of Patients''': 50 '''Recruitment Status''': RECRUITING '''Condition''': Multiple Myeloma '''NCTID''': NCT02596243 '''Title''': [[hasTrialTitle::Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)]] '''Study Summary''': The purpose of this study is to access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3) '''Sponsor''': Genexine, Inc. '''Intervention''': GX-188E '''Start Date''': 2015-08 '''Last Updated''': 2017-07-12 '''Number of Patients''': 134 '''Recruitment Status''': UNKNOWN '''Condition''': Cervical Intraepithelial Neoplasia '''NCTID''': NCT04770896 '''Title''': [[hasTrialTitle::A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab]] '''Study Summary''': This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab '''Start Date''': 2021-04-26 '''Last Updated''': 2023-11-13 '''Number of Patients''': 554 '''Recruitment Status''': RECRUITING '''Condition''': Unresectable Hepatocellular Carcinoma '''NCTID''': NCT02106546 '''Title''': [[hasTrialTitle::Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer]] '''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC). '''Sponsor''': AbbVie '''Intervention''': Carboplatin '''Start Date''': 2014-04-10 '''Last Updated''': 2020-11-17 '''Number of Patients''': 970 '''Recruitment Status''': COMPLETED '''Condition''': Squamous Non-Small Cell Lung Cancer '''NCTID''': NCT00400478 '''Title''': [[hasTrialTitle::A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13]] '''Study Summary''': This is a randomized, open label, phase III study to evaluate the ability of rituximab maintenance therapy to prolong event-free survival in aggressive NHL. Patients will be screened after successful standard induction therapy (CR or Cru following standard R-CHOP-like therapy with 8 infusions of rituximab plus CHOP-like chemotherapy (4-8 cycles). Patients will be followed until an event occurs as defined in the protocol. To evaluate the clinical efficacy of rituximab maintenance therapy as compared to observation in patients with aggressive B-cell Non-Hodgkins lymphoma or follicular lymphoma grade 3b who have achieved a complete remission after appropriate first-line therapy, measured by event-free survival (EFS), 440 patients with DLCBL or follicular NHL grade 3 (220 per arm) will be recruited. '''Sponsor''': Arbeitsgemeinschaft medikamentoese Tumortherapie '''Intervention''': Rituximab '''Start Date''': 2006-01 '''Last Updated''': 2016-05-26 '''Number of Patients''': 683 '''Recruitment Status''': COMPLETED '''Condition''': Diffuse Large B-Cell Lymphoma (DLBCL) '''NCTID''': NCT04688931 '''Title''': [[hasTrialTitle::A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer]] '''Study Summary''': This is a global, randomized, controlled, open-label Phase 3 study designed to assess the long-term efficacy and safety of UGN-102 (mitomycin) for intravesical solution with or without (±) transurethral resection of bladder tumors (TURBT) versus TURBT alone for the treatment of patients with low grade intermediate risk non-muscle invasive bladder cancer (LG IR NMIBC). '''Sponsor''': UroGen Pharma Ltd. '''Intervention''': UGN-102 '''Start Date''': 2021-02-19 '''Last Updated''': 2023-08-03 '''Number of Patients''': 282 '''Recruitment Status''': TERMINATED '''Condition''': Bladder Cancer '''NCTID''': NCT03104699 '''Title''': [[hasTrialTitle::Study of AGEN2034 in Advanced Tumors and Cervical Cancer]] '''Study Summary''': This is a 2-part trial: a Phase 1, open-label, dose-escalation study in subjects with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen. '''Sponsor''': Agenus Inc. '''Intervention''': AGEN2034 '''Start Date''': 2017-04-11 '''Last Updated''': 2023-06-05 '''Number of Patients''': 211 '''Recruitment Status''': COMPLETED '''Condition''': Advanced Cancer '''NCTID''': NCT04307576 '''Title''': [[hasTrialTitle::A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia]] '''Study Summary''': ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design. '''Sponsor''': Mats Heyman '''Intervention''': Omitted Doxorubicin '''Start Date''': 2020-07-13 '''Last Updated''': 2023-11-21 '''Number of Patients''': 6430 '''Recruitment Status''': RECRUITING '''Condition''': Leukemia, Acute Lymphoblastic '''NCTID''': NCT05052801 '''Title''': [[hasTrialTitle::Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression]] '''Study Summary''': The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants with FGFR2b ≥10% 2+/3+ tumor cell staining (FGFR2b ≥10% 2+/3+TC) '''Sponsor''': Amgen '''Intervention''': Bemarituzumab '''Start Date''': 2022-03-07 '''Last Updated''': 2023-11-18 '''Number of Patients''': 516 '''Recruitment Status''': RECRUITING '''Condition''': Gastric Cancer '''NCTID''': NCT01588184 '''Title''': [[hasTrialTitle::An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study]] '''Study Summary''': This single-arm, open-label, multicenter extension study will provide continued bevacizumab therapy to participants with solid tumors who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from the bevacizumab therapy. Participants will receive the same dose and regimen of bevacizumab as used in the previous parent trial and continue this treatment until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Bevacizumab '''Start Date''': 2012-07-13 '''Last Updated''': 2020-11-05 '''Number of Patients''': 95 '''Recruitment Status''': COMPLETED '''Condition''': Neoplasms '''NCTID''': NCT04380636 '''Title''': [[hasTrialTitle::Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)]] '''Study Summary''': The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC. Arms 1 and 2 will be studied in a double-blind design and Arm 3 will be open-label. The primary hypotheses are: 1. Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with olaparib is superior to concurrent chemoradiation therapy followed by durvalumab with respect to progression-free survival (PFS) and overall survival (OS) 2. Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab is superior to concurrent chemoradiation therapy followed by durvalumab with respect to PFS and OS '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab '''Start Date''': 2020-07-06 '''Last Updated''': 2023-11-07 '''Number of Patients''': 870 '''Recruitment Status''': RECRUITING '''Condition''': Lung Neoplasms '''NCTID''': NCT03989258 '''Title''': [[hasTrialTitle::Personalised Risk-based Breast Cancer Prevention and Screening]] '''Study Summary''': This is a cohort study, applied research and T3 translational genomics to estimate the impact of genetic risk for breast cancer detection in the screening program. The study group base consists of 28 389 female participants, currently in the age-group 22-79, in the Biobank of Estonian Genome Centre. The study is aimed to demonstrate the usability of personalised approach for adjusting and stratifying screening recommendations, based on predicted genetic risk estimates for breast cancer in the situation, where the genome data could be available from all women who have given informed consent for that. The project includes both the detection of moderate and high hereditary breast cancer risk carriers as well as high risk polygenic risk-score (consisting several single nucleotide polymorphisms) carriers among healthy individuals for application of personalised prevention and screening strategies. '''Sponsor''': Tartu University Hospital '''Intervention''': Mammography outside official screening '''Start Date''': 2018-10-01 '''Last Updated''': 2019-06-20 '''Number of Patients''': 28389 '''Recruitment Status''': UNKNOWN '''Condition''': Breast Cancer '''NCTID''': NCT05677958 '''Title''': [[hasTrialTitle::Protein Intake in Patients With Colorectal or Lung Cancer When Receiving a Nutritional Supplement]] '''Study Summary''': The PROTEOS study is an randomized controlled, open label, parallel-group, multi-centre and multicounty interventional study to assess the acceptance and implementation of Compact Protein, a low volume, energy dense and high protein oral nutritional support in clinical practice according to the ESPEN guidelines in colorectal and lung cancer patients undergoing chemo(radio)- or immunotherapy treatment. '''Sponsor''': Nutricia Research '''Intervention''': 125 mL Fortimel/Nutridrink Compact Protein '''Start Date''': 2019-01-17 '''Last Updated''': 2023-01-10 '''Number of Patients''': 126 '''Recruitment Status''': COMPLETED '''Condition''': Colorectal Cancer '''NCTID''': NCT05144841 '''Title''': [[hasTrialTitle::A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)]] '''Study Summary''': The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': MK-2140 (zilovertamab vedotin) '''Start Date''': 2022-01-08 '''Last Updated''': 2023-11-18 '''Number of Patients''': 140 '''Recruitment Status''': RECRUITING '''Condition''': Relapsed or Refractory Diffuse Large B-Cell Lymphoma '''NCTID''': NCT03911128 '''Title''': [[hasTrialTitle::A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia]] '''Study Summary''': The pilot study collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new platform protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised trials included in the study-design. The pilot study is implemented as a master protocol without study specific interventions, thus as an observational study. The pilot study is for countries/study-groups who intend to join ALLTogether1 (including experimental interventions). For these countries the pilot study is crucial to optimise diagnostics, registration systems, collaborations with vendors, logistics and data-checks before starting the main study. The study only includes "standard of care" treatment included in the master protocol. '''Sponsor''': Mats Heyman '''Intervention''': Observational '''Start Date''': 2019-08-29 '''Last Updated''': 2023-08-30 '''Number of Patients''': 500 '''Recruitment Status''': RECRUITING '''Condition''': Leukemia, Acute Lymphoblastic '''NCTID''': NCT02834884 '''Title''': [[hasTrialTitle::SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access]] '''Study Summary''': SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care. '''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC '''Intervention''': RP-1828 IMMUcan '''Start Date''': 2017-05-03 '''Last Updated''': 2023-11-03 '''Number of Patients''': 4975 '''Recruitment Status''': RECRUITING '''Condition''': All Tumor Types '''NCTID''': NCT02576574 '''Title''': [[hasTrialTitle::Avelumab in First-line NSCLC (JAVELIN Lung 100)]] '''Study Summary''': The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death ligand 1+ (PD-L1+) tumors. '''Sponsor''': EMD Serono Research & Development Institute, Inc. '''Intervention''': Avelumab '''Start Date''': 2015-10-29 '''Last Updated''': 2023-11-07 '''Number of Patients''': 1214 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': First Line Non-Small Cell Lung Cancer '''NCTID''': NCT02807636 '''Title''': [[hasTrialTitle::Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma]] '''Study Summary''': A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab '''Start Date''': 2016-06-30 '''Last Updated''': 2023-06-09 '''Number of Patients''': 1213 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Urothelial Carcinoma '''NCTID''': NCT03033511 '''Title''': [[hasTrialTitle::A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)]] '''Study Summary''': This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy. '''Sponsor''': AbbVie '''Intervention''': Placebo for dexamethasone '''Start Date''': 2017-02-07 '''Last Updated''': 2021-07-29 '''Number of Patients''': 748 '''Recruitment Status''': TERMINATED '''Condition''': Small Cell Lung Cancer <span style="display:none">hasTrialTitle::Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma</span> <span style="display:none">hasTrialTitle::Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)</span> <span style="display:none">hasTrialTitle::A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers</span> <span style="display:none">hasTrialTitle::Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer</span> <span style="display:none">hasTrialTitle::A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer</span> <span style="display:none">hasTrialTitle::A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors</span> <span style="display:none">hasTrialTitle::Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions</span> <span style="display:none">hasTrialTitle::Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)</span> <span style="display:none">hasTrialTitle::Validation of the European Oncology Quality of Life Toolkit</span> <span style="display:none">hasTrialTitle::Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment</span> <span style="display:none">hasTrialTitle::A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer</span> <span style="display:none">hasTrialTitle::A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma</span> <span style="display:none">hasTrialTitle::A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia</span> <span style="display:none">hasTrialTitle::Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA</span> <span style="display:none">hasTrialTitle::Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy</span> <span style="display:none">hasTrialTitle::Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia</span> <span style="display:none">hasTrialTitle::A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)</span> <span style="display:none">hasTrialTitle::A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma</span> <span style="display:none">hasTrialTitle::Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)</span> <span style="display:none">hasTrialTitle::Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)</span> <span style="display:none">hasTrialTitle::Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study</span> <span style="display:none">hasTrialTitle::A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract</span> <span style="display:none">hasTrialTitle::A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment</span> <span style="display:none">hasTrialTitle::A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer</span> <span style="display:none">hasTrialTitle::Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer</span> <span style="display:none">hasTrialTitle::A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis</span> <span style="display:none">hasTrialTitle::A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)</span> <span style="display:none">hasTrialTitle::Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer</span> <span style="display:none">hasTrialTitle::A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer</span> <span style="display:none">hasTrialTitle::A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)</span> <span style="display:none">hasTrialTitle::A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site</span> <span style="display:none">hasTrialTitle::Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study</span> <span style="display:none">hasTrialTitle::A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice</span> <span style="display:none">hasTrialTitle::A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer</span> <span style="display:none">hasTrialTitle::Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet</span> <span style="display:none">hasTrialTitle::A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma</span> <span style="display:none">hasTrialTitle::A Study of Vemurafenib in Participants With Metastatic Melanoma</span> <span style="display:none">hasTrialTitle::Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)</span> <span style="display:none">hasTrialTitle::Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients</span> <span style="display:none">hasTrialTitle::Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)</span> <span style="display:none">hasTrialTitle::A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab</span> <span style="display:none">hasTrialTitle::Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer</span> <span style="display:none">hasTrialTitle::A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13</span> <span style="display:none">hasTrialTitle::A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer</span> <span style="display:none">hasTrialTitle::Study of AGEN2034 in Advanced Tumors and Cervical Cancer</span> <span style="display:none">hasTrialTitle::A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia</span> <span style="display:none">hasTrialTitle::Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression</span> <span style="display:none">hasTrialTitle::An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study</span> <span style="display:none">hasTrialTitle::Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)</span> <span style="display:none">hasTrialTitle::Personalised Risk-based Breast Cancer Prevention and Screening</span> <span style="display:none">hasTrialTitle::Protein Intake in Patients With Colorectal or Lung Cancer When Receiving a Nutritional Supplement</span> <span style="display:none">hasTrialTitle::A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)</span> <span style="display:none">hasTrialTitle::A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia</span> <span style="display:none">hasTrialTitle::SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access</span> <span style="display:none">hasTrialTitle::Avelumab in First-line NSCLC (JAVELIN Lung 100)</span> <span style="display:none">hasTrialTitle::Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma</span> <span style="display:none">hasTrialTitle::A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)</span> <span style="display:none">hasCancerType::C00-D48: All neoplasms</span> <span style="display:none">hasCancerType::C00-C97: All cancer types</span> <span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span> <span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span> <span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span> <span style="display:none">hasCancerType::C40-C41: Bone cancers</span> <span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span> <span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span> <span style="display:none">hasCancerType::C50: Breast cancer</span> <span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span> <span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span> <span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span> <span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span> <span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span> <span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span> <span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span> <span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span> <span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span> <span style="display:none">hasCancerType::D10-D36: Benign tumour</span> <span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span> <span style="display:none">hasCancerType::unknown</span>
Summary:
Please note that all contributions to Beacon may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Beacon:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Tools
What links here
Related changes
Special pages
Page information
